CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its drug discovery and development programs and provide a general corporate overview at the Roth 22nd Annual Orange County Growth Stock Conference on Wednesday, March 17, at 1:30 p.m. PST (4:30 p.m. EST) at the Ritz Carlton Laguna Niguel in Dana Point, CA.
